GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akcea Therapeutics Inc (NAS:AKCA) » Definitions » Beneish M-Score

Akcea Therapeutics (Akcea Therapeutics) Beneish M-Score : -3.21 (As of Apr. 26, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Akcea Therapeutics Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.21 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Akcea Therapeutics's Beneish M-Score or its related term are showing as below:

AKCA' s Beneish M-Score Range Over the Past 10 Years
Min: -3.3   Med: 2.78   Max: 11.44
Current: -3.21

During the past 6 years, the highest Beneish M-Score of Akcea Therapeutics was 11.44. The lowest was -3.30. And the median was 2.78.


Akcea Therapeutics Beneish M-Score Historical Data

The historical data trend for Akcea Therapeutics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akcea Therapeutics Beneish M-Score Chart

Akcea Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Beneish M-Score
Get a 7-Day Free Trial - - - 11.44 1.70

Akcea Therapeutics Quarterly Data
Dec14 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.65 -0.90 1.70 -3.30 -3.21

Competitive Comparison of Akcea Therapeutics's Beneish M-Score

For the Biotechnology subindustry, Akcea Therapeutics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Akcea Therapeutics's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Akcea Therapeutics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Akcea Therapeutics's Beneish M-Score falls into.



Akcea Therapeutics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Akcea Therapeutics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.5366+0.528 * 0.9584+0.404 * 0.7652+0.892 * 1.5306+0.115 * 0.9159
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.6098+4.679 * -0.270445-0.327 * 0.6119
=-3.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun20) TTM:Last Year (Jun19) TTM:
Total Receivables was $14.0 Mil.
Revenue was 22.377 + 16.074 + 277.479 + 20.624 = $336.6 Mil.
Gross Profit was 17.331 + 11.291 + 272.449 + 18.223 = $319.3 Mil.
Total Current Assets was $428.2 Mil.
Total Assets was $527.9 Mil.
Property, Plant and Equipment(Net PPE) was $16.5 Mil.
Depreciation, Depletion and Amortization(DDA) was $7.6 Mil.
Selling, General, & Admin. Expense(SGA) was $174.7 Mil.
Total Current Liabilities was $35.2 Mil.
Long-Term Debt & Capital Lease Obligation was $13.5 Mil.
Net Income was -49.577 + -42.85 + 82.406 + -31.498 = $-41.5 Mil.
Non Operating Income was 0.909 + 1.641 + 0.884 + 1.351 = $4.8 Mil.
Cash Flow from Operations was -33.423 + -44.105 + 208.734 + -34.732 = $96.5 Mil.
Total Receivables was $17.1 Mil.
Revenue was 26.623 + 163.816 + 10.197 + 19.241 = $219.9 Mil.
Gross Profit was 20.84 + 161.372 + 7.408 + 10.297 = $199.9 Mil.
Total Current Assets was $327.7 Mil.
Total Assets was $434.1 Mil.
Property, Plant and Equipment(Net PPE) was $17.0 Mil.
Depreciation, Depletion and Amortization(DDA) was $6.9 Mil.
Selling, General, & Admin. Expense(SGA) was $187.2 Mil.
Total Current Liabilities was $50.6 Mil.
Long-Term Debt & Capital Lease Obligation was $14.9 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(14.049 / 336.554) / (17.104 / 219.877)
=0.041744 / 0.077789
=0.5366

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(199.917 / 219.877) / (319.294 / 336.554)
=0.909222 / 0.948716
=0.9584

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (428.173 + 16.541) / 527.937) / (1 - (327.711 + 16.977) / 434.12)
=0.157638 / 0.206008
=0.7652

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=336.554 / 219.877
=1.5306

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(6.862 / (6.862 + 16.977)) / (7.581 / (7.581 + 16.541))
=0.287848 / 0.314277
=0.9159

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(174.724 / 336.554) / (187.2 / 219.877)
=0.519156 / 0.851385
=0.6098

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((13.545 + 35.181) / 527.937) / ((14.909 + 50.569) / 434.12)
=0.092295 / 0.150829
=0.6119

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-41.519 - 4.785 - 96.474) / 527.937
=-0.270445

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Akcea Therapeutics has a M-score of -3.63 suggests that the company is unlikely to be a manipulator.


Akcea Therapeutics Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Akcea Therapeutics's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Akcea Therapeutics (Akcea Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
22 Boston Wharf Road, 9th Floor, Boston, MA, USA, 02110
Akcea Therapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. It is advancing a mature pipeline of novel drugs with the potential to treat multiple diseases. The company's drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc. Its most advanced drug, volanesorsen, has completed a Phase 3 clinical program for the treatment of familial chylomicronemia syndrome, or FCS, and is currently in Phase 3 clinical development for the treatment of familial partial lipodystrophy, or FPL.
Executives
Michael J. Yang director C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Joseph Iii Klein director C/O GENAISSANCE PHARMACEUTICALS INC, FIVE SCIENCE PARK, NEW HAVEN CT 06511
Sandford D Smith director C/O ARIAD PHARMACEUTICALS INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
B Lynne Parshall director 2855 GAZELLE COURT, CARLSBAD CA 92010
Joshua F. Patterson officer: General Counsel C/O AKCEA THERAPEUTICS, INC., 22 BOSTON WHARF ROAD, 9TH FLOOR, BOSTON MA 02210
Damien Mcdevitt director, officer: Chief Executive Officer C/O IONIS PHARMACEUTICALS, INC., 2855 GAZELLE COURT, CARLSBAD CA 92010
Alex G. Howarth officer: Chief Operating Officer C/O AKCEA THERAPEUTICS, INC., 22 BOSTON WHARF ROAD, 9TH FLOOR, BOSTON MA 02210
Kyle Jenne officer: Chief Commercial Officer C/O AKCEA THERAPEUTICS, INC. 22 BOSTON WHARF ROAD, 9TH FLOOR BOSTON MA 02210
William T. Andrews officer: Chief Medical Officer ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142
Barbara Yanni director 1018 W. 8TH AVENUE, SUITE A, KING OF PRUSSIA PA 19406
Michael Dennis Price officer: Chief Financial Officer
Elaine Hochberg director C/O AKCEA THERAPAEUTICS 55 CAMBRIDGE PKWY, STE 100 CAMBRIDGE MA 02142
Isis Pharmaceuticals Inc 10 percent owner 2855 GAZELLE COURT, CARLSBAD CA 92010
Michael F Maclean officer: Chief Financial Officer 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Paula Soteropoulos director, officer: Chief Executive Officer 49 WINONA STREET, PEABODY MA 01960